These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Effects of antiarrhythmic drugs on QT interval dispersion--relationship to antiarrhythmic action and proarrhythmia. Gillis AM Prog Cardiovasc Dis; 2000; 42(5):385-96. PubMed ID: 10768315 [TBL] [Abstract][Full Text] [Related]
29. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB; Circulation; 2009 Apr; 119(14):1883-91. PubMed ID: 19332468 [TBL] [Abstract][Full Text] [Related]
30. [QT dispersion intervals in hypertensives with left ventricular hypertrophy]. Ghanem Wisam MA; Murín J; Jaber J; Radman A; Bulas J; Kozliková K Vnitr Lek; 2001 Jan; 47(1):20-4. PubMed ID: 15635864 [TBL] [Abstract][Full Text] [Related]
31. Single-drug therapy and reduction of left ventricular mass in hypertension. Gottdiener JS Cardiologia; 1998 Nov; 43(11):1177-83. PubMed ID: 9922583 [TBL] [Abstract][Full Text] [Related]
32. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. Schmieder RE; Martus P; Klingbeil A JAMA; 1996 May; 275(19):1507-13. PubMed ID: 8622227 [TBL] [Abstract][Full Text] [Related]
33. [Effect of cilazapril therapy on diastolic filling and left ventricular hypertrophy in patients with arterial hypertension]. De Simone R; Irace L; Perna B; Caruso C; Guida M; Iacono A Minerva Cardioangiol; 1993 May; 41(5):205-9. PubMed ID: 8355860 [TBL] [Abstract][Full Text] [Related]
34. Subclinical ventricular repolarization abnormality in uncontrolled compared with controlled treated hypertension. Al-Nimer MSM; Hussein II Indian Heart J; 2017; 69(2):136-140. PubMed ID: 28460758 [TBL] [Abstract][Full Text] [Related]
35. [Antihypertensive treatment and left ventricular hypertrophy]. Agabiti-Rosei E; Muiesan ML; Rizzoni D Ann Ital Med Int; 1993 Oct; 8 Suppl():97S-103S. PubMed ID: 8117529 [TBL] [Abstract][Full Text] [Related]
36. Heart rate correction models to detect QT interval prolongation in novel pharmaceutical development. Markert M; Shen R; Trautmann T; Guth B J Pharmacol Toxicol Methods; 2011; 64(1):25-41. PubMed ID: 21635956 [TBL] [Abstract][Full Text] [Related]
37. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Wachtell K; Okin PM; Olsen MH; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Nieminen MS; Thygesen K Circulation; 2007 Aug; 116(7):700-5. PubMed ID: 17664372 [TBL] [Abstract][Full Text] [Related]
38. Autonomic modulation and QT interval dispersion in hypertensive subjects with anxiety. Piccirillo G; Viola E; Nocco M; Santagada E; Durante M; Bucca C; Marigliano V Hypertension; 1999 Aug; 34(2):242-6. PubMed ID: 10454448 [TBL] [Abstract][Full Text] [Related]
39. Left ventricular hypertrophy: how to influence an important risk factor in hypertension. Agabiti-Rosei E; Muiesan ML J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098 [TBL] [Abstract][Full Text] [Related]
40. Differential effects of antihypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) trial. Havranek EP; Esler A; Estacio RO; Mehler PS; Schrier RW; Am Heart J; 2003 Jun; 145(6):993-8. PubMed ID: 12796754 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]